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TO THE EDITOR
The frequency of BRAF mutations among
nevi is variable (Thomas, 2006), but little
is known about the frequency among
nevi, stratified by dermoscopy and by the
detection method.
In this study, we evaluated BRAF
status in 45 nevi from 43 patients
(23 women, mean age 39.9 years) using
the Sanger method (Loewe et al., 2004);
a random subset of 24 of these nevi was
tested by the more sensitive ultradeep
pyrosequencing (UDPS, Huse et al.,
2007; Tan et al., 2008; See Supplemen-
tary Data: Material and Methods S1,
Supplementary Tables S1 and S2 online).
RESULTS
Patient demographics, anatomic loca-
tion of nevi, dermoscopic patterns,
histopathological diagnosis, and results
of the genetic tests using Sanger
and UDPS are summarized in Table 1.
Dermoscopically, the 45 nevi consisted
of 17 (37.7%) reticular nevi (R), 5
(11.1%) globular nevi (G), 12 (26.6%)
mixed reticular nevi with central glo-
bules/homogeneous areas (MC), and 11
(24.4%) mixed reticular/homogeneous
nevi with peripheral globules (MP).
Using Sanger method, 6 of the 45
nevi (13.3%) contained BRAFV600E;
their dermoscopic patterns were G
(n¼2), MC (n¼ 2), and MP (n¼ 2),
and all (n¼6) were compound nevi on
histopathology. None of the nevi clas-
sified as R on dermoscopy or as jun-
ctional nevi on histopathology showed
BRAF mutations. Patients with nevi
harboring BRAFV600E were younger
than those with wild-type BRAF (30
versus 41 years, respectively; P¼0.03).
Using UDPS, 19 (79.2%) of the
24 randomly selected nevi were
BRAFV600E positive, including G nevi
(100%), MP nevi (90.9%), R nevi (75%),
and MC nevi (57%). Six nevi showed
heterogeneity of mutations (patients 3, 9,
14 and 16–18) and two nevi (patients 1
and 3), which were negative for
BRAFV600E, revealed p.K601E variant.
Representative electropherogramms are
depicted in Figure 1 (lanes 3 and 4).
There was no significant age difference
between patients with BRAFV600E nevi
and patient whose nevi showed wild-
type BRAF (37 versus 44 years, respec-
tively; P¼ 0.20).
COMMENT
The frequency of BRAF mutations
among nevi was highly dependent on
the sensitivity of the employed method;
only 13.3% of nevi showed BRAF
mutation using Sanger method,
whereas 79.2% showed mutation with
UDPS. The finding of BRAF mutation
by UDPS and not by Sanger method
probably attests to clonal heterogeneity
within the nevus, whereby clones of
BRAF mutations and clones with wild-
type BRAF coexist (Lin et al., 2009). The
age difference seen between patients
Abbreviations: G, globular nevi; MC, mixed reticular nevi with central globules/homogeneous areas;
MP, mixed reticular/homogeneous nevi with peripheral globules; R, reticular nevi; UDPS, ultradeep
pyrosequencing
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Table 1. Patient data, clinical characteristics, and detection rates of BRAF mutations among 45 nevi
Ref_BRAF coding position 1798:G/A 1799:T/A 1800:G/A 1801:A/G
Codon 600 600 600 601 600
Mutation GTG/ATG GTG/GAG GTG/GTA AAA/GAA GTG/GAG
ID DX HX Age, years Location Sex Variant (%) Variant (%) Variant (%) Variant (%) Reads Sanger
1 R Comp 40 Trunk F 0.3 0 0 2.79 7,608 GTG
2 R Junct 42 Abdomen F 0 0 0 0 13,959 GTG
3 MC Comp 37 Trunk F 1.34 0 0 3 11,423 GTG
4 MC Comp 36 Trunk M 0 0 0 3.38 7,042 GTG
5 MC Comp 46 Trunk F 0 0 0 0 11,986 GTG
6 MC Comp 61 Abdomen F 0 0 0 0 15,899 GTG
7 MC Comp 31 Trunk M 0 0.32 0 0 12,015 GTG
8 MP Comp 42 Trunk M 0 0.49 0 0.29 9,054 GTG
9 R Junct 46 Trunk M 1.41 1.08 0 0 11,370 GTG
10 MP Junct 23 Trunk F 0 1.36 0 0 14,359 GTG
11 MP Comp 54 Abdomen F 0.47 1.75 0 0 10,017 GTG
12 MP Comp 55 Abdomen M 0 2.83 0 0 10,736 GTG
13 MP Comp 19 Trunk F 0.91 3.76 0 0.32 10,047 GTG
14 MP Comp 30 Trunk F 2.18 4.55 0 0.41 4,919 GTG
15 MP Comp 34 Trunk F 0 4.63 0 0 10,101 GTG
16 MP Comp 26 Abdomen M 1.58 4.91 0 0 6,399 GaG
17 MC Comp 58 Abdomen M 1.03 5.62 0.84 0 7,746 GTG
18 MP Comp 31 Trunk M 1.35 6.72 0 0 10,000 GTG
19 MP Comp 38 Extremity M 0.41 7.34 0 0 9,021 GAG
20 MP Comp 26 Trunk F 0 10.54 0 0 11,163 GTG
21 MC Comp 27 Abdomen M 0 10.62 0 0 6,525 GTG
22 G Comp 52 Trunk M 0 11.12 0 0 14,949 GTG
23 R Comp 39 Abdomen M 0 15.38 0 0 10,343 GTG
24 G Derm 27 Extremity F 0 28.59 0 0 10,118 GAG
25 G Comp 24 Trunk F / / / / / GAG
26 MC Comp 35 Extremity F / / / / / GaG
27 MC Comp 32 Trunk F / / / / / GAG
28 R Junct 55 Extremity F / / / / / GTG
29 R Junct 39 Trunk M / / / / / GTG
30 R Junct 46 Extremity M / / / / / GTG
31 R Junct 37 Abdomen F / / / / / GTG
32 R Comp 35 Trunk F / / / / / GTG
33 R Comp 44 Trunk F / / / / / GTG
34 R Comp 44 Trunk M / / / / / GTG
35 R Comp 25 Extremity F / / / / / GTG
36 R Comp 38 Trunk F / / / / / GTG
37 R Comp 38 Abdomen F / / / / / GTG
38 R Junct 39 Trunk M / / / / / GTG
39 R Comp 49 Trunk F / / / / / GTG
40 R Comp 34 Trunk M / / / / / GTG
Table 1 continued on the following page
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with BRAFV600E nevi and patients with
wild-type nevi was only found using
Sanger method, but not with UDPS.
Although marked differences between
the methods were found in BRAF
mutation frequency among R nevi
(0% by Sanger and 75% by UDPS),
both methods found BRAF mutations to
be more frequent among nevi classified
as G and MP by dermoscopy and as
dermal and compound nevi by histo-
pathology.
These findings suggest that BRAF-
mutant clones predominate in younger
age, and possibly in G nevi (Table 1),
which mostly correlate with compound
or dermal nevi on histopathology. In
contrast, among R nevi, which usually
are predominantly junctional nevi,
BRAF-mutated clones are the minority.
This challenges the theory of nevogen-
esis, which states that intermittent UV
exposure induces BRAF mutations,
which in turn stimulate melanocytic
proliferation (Wu et al., 2007). One
would expect, by this theory, a higher
frequency of BRAF mutations among
nevi that are predominantly junctional
(for example, R nevi) than in nevi that
are predominantly dermal (for example,
G nevi); junctional melanocytes are
likely to be exposed to higher levels of
UV than dermal melanocytes. The
reports of high rates of BRAF mutations
among nevi from sun-protected body
areas (Wu et al., 2007; Takata et al.,
2010) further doubt the notion that UV
exposure has an important role in
acquisition of BRAF mutations.
The finding that BRAF mutation
among nevi is age related is interesting,
as the dermoscopic pattern of nevi
was also found to be age dependent
(Zalaudek et al., 2006; Scope et al.,
Table 1. Continued
Ref_BRAF coding position 1798:G/A 1799:T/A 1800:G/A 1801:A/G
Codon 600 600 600 601 600
Mutation GTG/ATG GTG/GAG GTG/GTA AAA/GAA GTG/GAG
ID DX HX Age, years Location Sex Variant (%) Variant (%) Variant (%) Variant (%) Reads Sanger
41 G Derm 62 Trunk M / / / / / GTG
42 G Comp 40 Abdomen F / / / / / GTG
43 MC Junct 37 Abdomen F / / / / / GTG
44 MC Comp 33 Trunk M / / / / / GTG
45 MC Junct 57 Trunk M / / / / / GTG
Abbreviations: Comp, compound nevus; Derm, dermal nevus; F, female; G, globular; Junct, junctional nevus; M, male; MC, mixed pattern with central
globules or structureless areas; MP, mixed pattern with peripheral globules; R, reticular.
Columns from left to right: (1) Patient ID; (2) Dermoscopic pattern of nevi; (3) Histopathological diagnosis of nevi; (4) Age; (5) Location of nevi;
(6) Sex; (7–11) Results from ultradeep pyrosequencing; (12) Results from Sanger sequencing. Sanger results with background levels indicating a minor
A—variants are denoted as GaG. Data showing mutations in BRAF are given in bold.
448 504 560 616 672 728 784
448 504 560 616 672 728
392 448 504 560 616 672 728





Figure 1. Electropherogramms of the BRAF mutation hotspot at codon 600 (c.1798-1800GTG) obtained
by Sanger sequencing from formalin-fixed paraffin-embedded specimens. Lane 1: sample ID7723
(wild-type sequence; validated by UDPS); lanes 2–4: samples ID16837 (c.T1799A mutation), ID31824
and ID44104 (both annotated ‘‘GaG’’ because of ‘‘background’’ levels of the A residue), respectively.
Samples ID31824 and ID44104 were tested to be c.T1799A mutation positive by UDPS. NCBI Reference
Sequence: NM_004333; Homo sapiens v-raf murine sarcoma viral oncogene homolog B1 (BRAF).
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2008). Most nevi before puberty are G
nevi, whereas MP nevi are most com-
monly seen during puberty and adoles-
cence (Kittler et al., 2000). Using digital
dermoscopic follow-up, MP pattern
was shown to indicate nevus growth;
MP nevi enlarge symmetrically,
while progressively developing central
network or structureless brown area,
until finally, the peripheral globules
disappear indicating that active growth
has ceased. At this stage, nevi reveal
either R or MC pattern. Indeed, in
adults, nevi mostly show the R pattern
and, to a lesser extent, the MC pattern.
The observation that BRAF muta-
tions are frequent among nevi whose
onset is during early childhood (G nevi)
and among growing nevi (MP nevi)
during adolescence, supports the hy-
pothesis that BRAF mutations are ac-
quired early in nevogenesis; it also
stands to reason that BRAF-mutant cells
affect the nevus’ phenotype (for example,
dermoscopic pattern). Furthermore, our
findings are in line with a previous study
reporting a 13-fold higher frequency of
BRAFV600E in growing compared with
stable melanocytic neoplasms (Loewe
et al., 2004); in their series, 5 of 20
changing nevi (25%) harbored
BRAFV600E, as detected by Sanger se-
quencing, whereas only 2 of 35 stable
nevi (6%) were BRAFV600E positive.
If MC- and R nevi represent a later
phase in the life of a nevus, while MP
pattern represents an early stage, it
seems reasonable that BRAF-mutant
clones predominate in nevi during their
growth phase. Thus, BRAF-mutant cells
differentially contribute to the life of
nevi. Indeed, previous studies showed
that, initially, abnormal BRAF expres-
sion leads to moderate melanocyte
proliferation, whereas sustained expres-
sion leads to oncogene-induced senes-
cence, attributed to the induction
of p16INK4a and acidic b-galactosidase
activity, and to cell-cycle arrest
(Michaloglou et al., 2005; Gray-Schop-
fer et al., 2006; Houben et al., 2009;
Scurr et al., 2010).
Our study has several limitations:
first, the sample number is small,
particularly because nevi were subca-
tegorized by dermoscopic pattern.
Second, we were able to perform UDPS
in only a subset of nevi; however, we
attempted to mitigate sampling bias by
randomly selecting nevi for UDPS
testing. Third, the discordant results of
BRAF mutations among R nevi obtained
by Sanger and UDPS methods, pre-
cludes definitive conclusions for this
nevus subtype.
In summary, this study demonstrates
that the frequency and predominance
of BRAF mutations in nevi depends on
dermoscopic pattern, the histopatho-
logical subtype, and the stage of nevus
development. Moreover, the method
employed to test BRAF mutations
strongly impacts the observed mutation
frequency; therefore, comparison be-
tween studies should take into account
the detection methods. Future studies
analyzing genetic alterations in nevi
should consider stratifying nevi by der-
moscopic pattern and by growth phase.
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